AbCellera Biologics (NASDAQ: ABCL) is a clinical-stage biotechnology company that discovers and develops antibody medicines using its proprietary drug discovery and development platform. The company transitioned from a partnership model to building its own internal pipeline in late 2023, completing that transition in mid-2025 when it advanced its first two programs into clinical trials. Revenue has historically come from partner-initiated programs through near-term access and research payments, clinical and commercial milestone payments, and royalties on net sales of drugs developed by partners. As of December 31, 2025, AbCellera had approximately $700 million in available liquidity and expects to generate losses and negative operating cash flow in the near-to-medium term. The company is headquartered in Vancouver, Canada, and operates a 130,000-square-foot clinical manufacturing facility completed in 2025. Its pipeline includes ABCL635 (targeting menopausal vasomotor symptoms) and ABCL575 (targeting atopic dermatitis), both in clinical trials, with development candidates ABCL688 and ABCL386 in IND-enabling activities as of FY2025.

Revenue model

Historically generated through three streams from partner-initiated antibody discovery programs: near-term payments for access, research, and intellectual property rights; downstream clinical and commercial milestone payments; and royalties on net sales of partner-developed drugs. The company is transitioning toward future revenues from out-licensing its own pipeline programs, milestones, and royalties.

Products and services

Antibody drug discovery and development platform. Internal pipeline as of FY2025: ABCL635 (anti-NK3R monoclonal antibody, Phase 1/2, menopausal vasomotor symptoms); ABCL575 (anti-OX40L monoclonal antibody, Phase 1, atopic dermatitis); ABCL688 and ABCL386 (development candidates, IND-enabling activities, Phase 1/2 trials anticipated 2027). Clinical manufacturing facility in Vancouver opened 2025.

Customers and end markets

Historical customers were pharmaceutical and biotechnology partners seeking antibody drug discovery capabilities. End markets include endocrinology, women's health, immunology, autoimmunity, and oncology.

Value-chain role

Drug discovery and development company. Historically operated as an upstream discovery partner delivering optimized antibodies to pharmaceutical companies. Now transitioning to a clinical-stage developer advancing proprietary drug candidates through its own pipeline.

Geographic exposure

Headquartered in Vancouver, Canada. Clinical manufacturing facility located in Vancouver. Files with the SEC as a foreign private issuer reporting in U.S. dollars.

Source: SEC 10-K, filed 2026-02-24

Industry: Pharmaceutical Preparations Peers: MindWalk Holdings Corp